US8609680B2 - 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives - Google Patents

2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives Download PDF

Info

Publication number
US8609680B2
US8609680B2 US13/049,225 US201113049225A US8609680B2 US 8609680 B2 US8609680 B2 US 8609680B2 US 201113049225 A US201113049225 A US 201113049225A US 8609680 B2 US8609680 B2 US 8609680B2
Authority
US
United States
Prior art keywords
dihydro
diazaspiro
inden
nonane
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/049,225
Other languages
English (en)
Other versions
US20110230461A1 (en
Inventor
Samit K. Bhattacharya
Kimberly O. Cameron
Dilinie P. Fernando
Kim F. McClure
Daniel W. Kung
Allyn T. Londregan
Suvi T. M. Simila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US13/049,225 priority Critical patent/US8609680B2/en
Publication of US20110230461A1 publication Critical patent/US20110230461A1/en
Priority to US14/083,275 priority patent/US20140080756A1/en
Application granted granted Critical
Publication of US8609680B2 publication Critical patent/US8609680B2/en
Assigned to PFIZER INC. reassignment PFIZER INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BHATTACHARYA, SAMIT K., CAMERON, KIMBERLY O., FERNANDO, DILINIE P., SIMILA, SUVI T.M.
Assigned to PFIZER INC. reassignment PFIZER INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAMERON, KIMBERLY O., BHATTACHARYA, SAMIT K., KUNG, DANIEL W., MCCLURE, KIM F.
Assigned to PFIZER INC. reassignment PFIZER INC. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNORS' NAMES AND EXECUTION DATES PREVIOUSLY RECORDED AT REEL: 035155 FRAME: 0362. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: BHATTACHARYA, SAMIT K., CAMERON, KIMBERLY O., FERNANDO, DILINIE P., KUNG, DANIEL W., LONDREGAN, ALLYN T., MCCLURE, KIM F., SIMILA, SUVI T.M.
Assigned to PFIZER INC. reassignment PFIZER INC. ASSIGNEE ADDRESS CORRECTION Assignors: PFIZER INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives, as well as pharmaceutical compositions and uses thereof as ghrelin inverse agonists or antagonists.
  • Diabetes mellitus is a condition in which the body either does not produce enough, or does not properly respond to, insulin, a hormone produced in the pancreas.
  • Type 1 diabetes is when the body does not produce insulin, of which only 5-10% of people with diabetes have Type 1 diabetes. 23.6 million children and adults in the United States have Type 2 diabetes (T2D; www.diabetes.org).
  • T2D either the body does not produce enough insulin or cells in the body do not response to insulin resulting in high levels of sugar in the blood.
  • Pregnant women who have never had diabetes before but who have high blood glucose levels during pregnancy are said to have gestational diabetes.
  • Gestational diabetes affects about 4% of all pregnant women and may precede development of T2D.
  • Ghrelin is an acylated 28 amino acid peptide which in 1999 was discovered to be the endogenous ligand of the growth hormone secretagogue receptor (GHS-R; Kojima et al., 1999).
  • GHS-R growth hormone secretagogue receptor
  • the n-octanoyl group at serine 3 of ghrelin is essential for GHS-R binding and function, whereas the unacylated des-acyl ghrelin, does not activate the GHS-R (Kojima et al., 1999; 2001; Boglio et al., 2003b).
  • Ghrelin is predominantly expressed in specialized cells located within the gastric oxyntic mucosa which provides the major source of circulating ghrelin (Date et al., 2000; Ariyasu et al., 2001; Dornonville de la Cour et al., 2001; Rindi et al., 2002).
  • ghrelin-producing epsilon cells have been identified in the developing and adult human pancreas (Wierup et al., 2002; Andralojc et al., 2009) and to a lesser extent in the intestine, kidney, immune system, placenta, testis, pituitary, lung and hypothalamus (Kojima et al., 1999; Hosoda et al., 2000; Date et al., 2000; Mori et al., 2000; Gualillo et al., 2001; Tanaka et al., 2001; Date et al., 2002; Gnanapavan et al., 2002; Hattori et al., 2001; Lu et al., 2002; Mucciolo et al., 2002; Sakata et al., 2002; Tena-Sempere et al., 2002; Volante et al., 2002 a,b; Mondal et
  • ghrelin is the only identified hunger hormone.
  • the preprandial rise and postprandial fall in plasma ghrelin levels support the hypothesis that ghrelin plays a physiological role in meal initiation in humans (Cummings et al., 2001).
  • the baseline and pulsatile pattern of ghrelin is inhibited in obese subjects following gastric bypass surgery (Cummings et al., 2002; Roth et al., 2008).
  • Endogenous acylated ghrelin has been reported to be elevated in obese T2D (Rodriguez et al., 2009) and these levels have an inverse correlation with insulin sensitivity (Barazzoni et al., 2007).
  • Exogenous ghrelin also increases blood glucose and decreases insulin levels in humans and rodents (Broglio et al., 2001, 2002, 2003a,b; Arosia et al., 2003; Broglio et al., 2004; Sun et al., 2006; Dezaki et al., 2004).
  • the ghrelin-induced hyperglycemia is abolished by the peptide GHS-R antagonist [D-Lys 3 ]-GHRP-6 (Dezaki et al., 2004).
  • ghrelin infusion in rodents and humans inhibits glucose-stimulated insulin secretion in vivo (Reimer et al., 2003; Dezaki et al., 2007; Tong et al., 2009).
  • Exogenous ghrelin also decreases glucose-induced insulin release in rat and mouse islets and in the rat perfused pancreas (Egido et al., 2002; Colombo et al., 2003; Reimer et al., 2003; Dezaki et al., 2004; Dezaki et al., 2006).
  • Dezaki et al. (2004; 2006; 2007; 2008) provided the first evidence to support the hypothesis that endogenous ghrelin in rodent islets acts directly on ⁇ -cells to inhibit glucose-induced insulin, as the peptide GHS-R antagonist and a ghrelin anti-serum increased intracellular calcium in response to glucose.
  • glucose-induced insulin release from isolated islets of ghrelin knock-out mice is greater than wild type.
  • the inhibitory effects of ghrelin on glucose-induced changes in intracellular calcium is abolished by pertussis toxin, an inhibitor of G i/o subtypes of GTP binding proteins.
  • GHS-R peptide antagonists have been reported to reduce fasting blood glucose in mice (Asakawa et al., 2003; Dezaki et al., 2004). More recently, a small molecule non-peptide antagonist has been shown to improve glucose tolerance in rats by stimulating insulin release without hypoglycemia (Elser et al., 2007).
  • exogenous ghrelin has been shown to modulate insulin sensitivity.
  • Intravenous infusion of ghrelin in man increases plasma glucose, increases free fatty acids, and reduces glucose disposal rates compatible with an impairment of insulin sensitivity (Gauna et al., 2004; Lucidi et al., 2005; Damjanovic et al., 2006; Vestergaard et al., 2007; 2008a, b).
  • GHS-R knock-out mice fed a high-fat diet had several measures of greater insulin sensitivity, including: lower fasted blood glucose and plasma insulin, lower % HbA1c, lower insulin levels during glucose tolerance tests, and improved performance in hyperinsulinemic-euglycemic and hyperglycemic clamp studies.
  • the knockout mice fed a high-fat diet also did not develop hepatic steatosis and had lower total cholesterol, relative to controls. Furthermore, the knock-out demonstrated a lower intestinal triglyceride secretion rate of dietary lipid.
  • ghrelin increases food intake in rodents (see Chen et al., 2009).
  • acute administration of exogenous ghrelin has been shown to stimulate food intake humans (Wren et al., 2001; Druce et al., 2005; Huda et al., 2009).
  • Several lines of evidence support a role for endogenous ghrelin in the control of food intake.
  • Anti-ghrelin antibodies and knockdown of the GHS-R suppress food intake in rats (Nakazato et al., 2001, Shuto et al, 2002).
  • Ghrelin knockout mice Both ghrelin knockout and GHS-R null mice have been reported by separate groups (Zigman et al., 2005; Wortley et al., 2005). GHS-R null mice were leaner than wild type when fed normal chow and were resistant to high fat diet-induced obesity. Ghrelin knock-out mice also have a reduced Respiratory Quotient, suggesting that ghrelin may act as a nutrient sensor and its absence may promote increased fat utilization.
  • the present invention provides compounds of Formula (I) that act as ghrelin inverse agonists or antagonists; and therefore, may be used in the treatment of diseases mediated by such antagonism or inverse agonism (e.g., diseases related to type 2 diabetes, and diabetes-related and obesity-related co-morbidities).
  • diseases mediated by such antagonism or inverse agonism e.g., diseases related to type 2 diabetes, and diabetes-related and obesity-related co-morbidities.
  • An embodiment of the present invention is the compound of Formula (I)
  • R 1 is -L 1 -R 1′ , phenyl or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, where said phenyl or said 5- to 6-membered heteroaryl is optionally fused to a (C 4 -C 7 )cycloalkyl, (C 5 -C 6 )cycloalkenyl, phenyl, saturated or partially unsaturated 5- to 6-membered heterocyclyl containing 1 to 4 heteroatoms each independently selected from N, O or S, or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, wherein said optionally fused phenyl and said optionally fused 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents selected from halo, hydroxy, oxo, cyano, (C 1 -C 3 )alkyl, halo-substituted (
  • R 1′ is phenyl or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, where said phenyl or said 5- to 6-membered heteroaryl is optionally fused to a (C 4 -C 7 )cycloalkyl, (C 5 -C 6 )cycloalkenyl, phenyl, saturated or partially unsaturated 5- to 6-membered heterocyclyl containing 1 to 4 heteroatoms each independently selected from N, O or S, or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, wherein said optionally fused phenyl and said optionally fused 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents selected from halo, hydroxy, oxo, cyano, (C 1 -C 3 )alkyl, halo-substituted (C 1 -C 3 )alky
  • L 1 is O, S, NH, N(C 1 -C 3 )alkyl or (C 1 -C 3 )alkylene;
  • R a at each occurrence is independently selected from hydrogen, (C 1 -C 3 )alkyl and halogen;
  • Z, Z 1 and Z 2 are each independently N or CH optionally substituted with halo, (C 1 -C 3 )alkoxy or (C 1 -C 3 )alkyl;
  • L is a direct bond, O, S, NH, N(C 1 -C 3 )alkyl or (C 1 -C 3 )alkylene;
  • R 2 is hydrogen, halo, cyano, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, phenyl, saturated or partially unsaturated 5- to 6-membered heterocyclyl containing 1 to 4 heteroatoms each independently selected from N, O or S, or 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, where said (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, phenyl, saturated or partially unsaturated 5- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, (C 1 -C 3 )alkyl, halo-substituted (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, halo-
  • n at each occurrence is independently 0, 1 or 2;
  • R x and R y at each occurrence are independently selected from hydrogen and (C 1 -C 6 )alkyl where said (C 1 -C 6 )alkyl is optionally interrupted with one or two groups independently selected from NH, N(C 1 -C 3 )alkyl, O and S, and is optionally substituted with 1 to 4 halo; or R x and R y taken together are a (C 2 -C 6 )alkylene which is optionally interrupted with one or two groups independently selected from NH, N(C 1 -C 3 )alkyl, O and S; or a pharmaceutically acceptable salt thereof.
  • R 1 is phenyl or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, where said phenyl or said 5- to 6-membered heteroaryl is optionally fused to a (C 4 -C 7 )cycloalkyl, (C 5 -C 6 )cycloalkenyl, phenyl, saturated or partially unsaturated 5- to 6-membered heterocyclyl containing 1 to 4 heteroatoms each independently selected from N, O or S, or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from N, O, or S, wherein said optionally fused phenyl and said optionally fused 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents selected from halo, hydroxy, oxo, cyano, (C 1 -C 3 )alkyl, halo-substi
  • R 1 is phenyl, naphthyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, thiazolyl, oxazolyl, thiazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridinyl, 2,3-dihydrofurano[3,2-b]pyridinyl, indolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, [1,2,4]triazolo[4,3-a]pyridine, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyrazolo[1,5-a]pyridinyl, 4,5,6,7-t
  • R 1 is phenyl, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, imidazo[2,1-b][1,3,4]thiadiazolyl, 1H-indazolyl, pyridazinyl, imidazo[1,2-b][1,2,4]triazinyl, 1H-pyrazolo[3,4-b]pyridinyl, imidazo[1,2-b]pyridazinyl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl, oxadiazolyl or imidazo[1,2-a]pyridinyl; each optionally substituted with 1 to 3 substituents independently selected from methyl, me
  • a further embodiment of the present invention is the compound of Formula (I) wherein L is a direct bond; and R 2 is hydrogen, phenyl, phenoxy, pyrimidinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, triazinyl or pyrazinyl; each optionally substituted with 1 to 3 substituents independently selected from methyl, trifluoromethyl, ethyl, methoxy, cyano or —C(O)NH 2 ; or a pharmaceutically acceptable salt thereof.
  • Yet another embodiment of the present invention is the compound of Formula (IA)
  • R 1 , R 2 and L are as described herein.
  • a further embodiment of the present invention is the compound of Formula (IA) wherein R 1 is phenyl, naphthyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, thiazolyl, oxazolyl, thiazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridinyl, 2,3-dihydrofurano[3,2-b]pyridinyl, indolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, [1,2,4]triazolo[4,3-a]pyridine, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyrazolo[1,5-a]pyridinyl, 4,5,6,
  • Yet another embodiment of the present invention is the compound of Formula (IA) wherein R 2 is phenyl, pyrimidinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazolyl, oxadiazolyl, pyrimidinyl, pyrazolyl, pyridazinyl, triazinyl or pyrazinyl each optionally substituted with 1 to 3 substituents independently selected from methyl, ethyl, methoxy, cyano or —C(O)NH 2 ; and L is a direct bond or O; or a pharmaceutically acceptable salt thereof.
  • Still another embodiment of the present invention is the compound of Formula (IA) wherein R 2 is phenyl, pyrimidinyl, triazolyl, thiazolyl, pyridinyl, oxazolyl, pyrimidinyl, pyrazolyl, or pyrazinyl; each optionally substituted with 1 to 3 substituents independently selected from methyl, ethyl, methoxy, cyano or —C(O)NH 2 ; and L is a direct bond; or a pharmaceutically acceptable salt thereof.
  • compositions that comprises (1) a compound of the present invention, and (2) a pharmaceutically acceptable excipient, diluent, or carrier.
  • the composition comprises a therapeutically effective amount of a compound of the present invention.
  • the composition may also contain at least one additional pharmaceutical agent (described herein).
  • Preferred agents include anti-obesity agents and/or anti-diabetic agents (described herein below).
  • in yet another aspect of the present invention is a method for treating a disease, condition, or disorder mediated by the Ghrelin receptor, in particular, by antagonism of said receptor, in a mammal that includes the step of administering to a mammal, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
  • Diseases, disorders, or conditions mediated by the Ghrelin receptor include but are not limited to type II diabetes, hyperglycemia, metabolic syndrome, impaired glucose tolerance, glucosuria, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, obesity, dyslididemia, hypertension, hyperinsulinemia, and insulin resistance syndrome.
  • Preferred diseases, disorders, or conditions include type II diabetes, hyperglycemia, impaired glucose tolerance, obesity, and insulin resistance syndrome. More preferred are type II diabetes, hyperglycemia, and obesity. Most preferred is type II diabetes.
  • in yet another aspect of the present invention is a method of reducing the level of blood glucose in a mammal, preferably a human, which includes the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
  • Compounds of the present invention may be administered in combination with other pharmaceutical agents (in particular, anti-obesity and anti-diabetic agents described herein below).
  • the combination therapy may be administered as (a) a single pharmaceutical composition which comprises a compound of the present invention, at least one additional pharmaceutical agent described herein and a pharmaceutically acceptable excipient, diluent, or carrier; or (b) two separate pharmaceutical compositions comprising (i) a first composition comprising a compound of the present invention and a pharmaceutically acceptable excipient, diluent, or carrier, and (ii) a second composition comprising at least one additional pharmaceutical agent described herein and a pharmaceutically acceptable excipient, diluent, or carrier.
  • the pharmaceutical compositions may be administered simultaneously or sequentially and in any order.
  • alkyl refers to a hydrocarbon radical of the general formula C n H 2n+1 .
  • the alkane radical may be straight or branched.
  • (C 1 -C 6 )alkyl refers to a monovalent, straight, or branched aliphatic group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, and the like).
  • (C 0 -C 3 )alkyl indicates that the alkyl moiety is not present when it is “C 0 ” or can have up to three carbons present.
  • alkyl portion (i.e., alkyl moiety) of an alkoxy, acyl (e.g., alkanoyl), alkylamino, dialkylamino, alkylsulfonyl, and alkylthio group have the same definition as above.
  • the alkane radical or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally, one to three substituents except in the case of halogen substituents such as perchloro or perfluoroalkyls) independently selected from the group of substituents listed below in the definition for “substituted.”
  • Halo-substituted alkyl refers to an alkyl group substituted with one or more halogen atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, 1,1-difluoroethyl and the like). Where “C 0 ” is indicated the carbon is absent and thus represents a direct bond.
  • cycloalkyl refers to nonaromatic carbocyclic rings that are fully saturated and may exist as a single ring, bicyclic ring or a spiro ring. Unless specified otherwise, the carbocyclic ring is generally a 3- to 8-membered ring.
  • cycloalkyl include groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, and the like.
  • cycloalkenyl refers to nonaromatic carbocyclic rings that are not fully saturated and may exist as a single ring, bicyclic ring or a spiro ring. Unless specified otherwise, the carbocyclic ring is generally a 5- to 8-membered ring.
  • cycloalkenyl include groups such as cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, and the like.
  • heterocyclyl refers to nonaromatic rings that are fully saturated or partially unsaturated (but not a fully unsaturated heteroaromatic) and may exist as a single ring, bicyclic ring or a spiro ring.
  • the heterocyclic ring is generally a 3- to 6-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen and/or nitrogen.
  • Heterocyclic rings include groups such as epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, N-methylpyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, and the like.
  • 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms refers to a radical of a 5 or 6 membered heteroaromatic ring which may contain 1 to 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • groups include, but are not limited to, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, thiadiazolyl, triazolyl, or tetrazolyl.
  • the “5- to 6-membered heteroaryl containing 1 to 4 heteroatoms” is optionally fused to a saturated, partially unsaturated or fully unsaturated cycloalkyl or a saturated, partially unsaturated or fully unsaturated 5 to 6 membered heterocycle.
  • the fused cycloalkyl group thus may contain double bonds and be partially unsaturated.
  • the fused cycloalkyl group may be derived from a saturated ring such as cyclopentane or cyclohexane.
  • the optionally fused cycloalkene can be a partially unsaturated ring such as cyclopentene or cyclohexene.
  • the optionally fused group can be a phenyl group.
  • the fused heterocyclyl group may be derived from a saturated heterocycle such as pyrrolidine a partially unsaturated heterocycle such as dihydropyrrole.
  • the optionally fused group can also be a fully unsaturated heteroaryl group such as pyrrole.
  • terapéuticaally effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
  • animal refers to humans (male or female), companion animals (e.g., dogs, cats and horses), food-source animals, zoo animals, marine animals, birds and other similar animal species.
  • companion animals e.g., dogs, cats and horses
  • food-source animals e.g., zoo animals, marine animals, birds and other similar animal species.
  • Edible animals refers to food-source animals such as cows, pigs, sheep and poultry.
  • phrases “pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • treating embrace both preventative, i.e., prophylactic, and palliative treatment.
  • antagonist includes both full antagonists and partial antagonists, as well as inverse agonists.
  • mediated refers to the treatment or prevention the particular disease, condition, or disorder, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease, condition, or disorder, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease, condition, or disorder described herein, by acting as an antagonist or inverse agonist at the Ghrelin receptor.
  • compounds of the present invention refer to compounds of Formulae (I) and (IA) and any pharmaceutically acceptable salts of the compounds, as well as, all stereoisomers (including diastereoisomers and enantiomers), tautomers, conformational isomers, and isotopically labeled compounds. Hydrates and solvates of the compounds of the present invention are considered compositions of the present invention, wherein the compound is in association with water or solvent, respectively. It is to be understood that the compounds of the invention can be named using different nomenclature systems and thus different synonyms can exist for the same compound.
  • FIG. 1 provides results from the Human Dispersed Islet Cell Assay.
  • the assay results show the measured insulin concentration when the assay is run in the presence of 3 mM glucose, 11 mM glucose, 11 mM glucose+test compound, 16 mM glucose and 22 mM glucose.
  • the test compounds designated as compounds A, B and C are the compounds of Examples 3A, 3B and 6E, respectively.
  • ANOVA was used to test the null hypothesis of equal treatment means. P-values from post-hoc pairwise comparisons were unadjusted.
  • Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis , v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
  • reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates.
  • Examples section below For a more detailed description of the individual reaction steps, see the Examples section below.
  • Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds.
  • specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions.
  • many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • N-Pg Suitable amino-protecting groups
  • BOC t-butoxycarbonyl
  • Cbz benzyloxycarbonyl
  • Fmoc 9-fluorenylmethyleneoxycarbonyl
  • Reaction Scheme I outlines the general procedures that can be used to provide compounds of the present invention having Formula (I).
  • Intermediate (1a) may be prepared by incorporating the desired amino-protecting group onto 2,7-diazaspiro[3.4]nonane.
  • a preferred amino-protecting group is a carbamate group such as t-butyoxycarbonyl (BOC) or benzyloxycarbonyl (Cbz).
  • Intermediate (1b) may be made from Intermediate (1a) by reaction with a carboxylic acid of the formula R 1 CH 2 CO 2 H where R 1 is as described above.
  • Suitable conditions include combining the acid and amine with a carbodiimide reagent such as dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) in a reaction inert solvent such as dichloromethane or acetonitrile at a temperature between ⁇ 10° C. to 30° C., preferably 0° C.
  • a carbodiimide reagent such as dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI)
  • a reaction inert solvent such as dichloromethane or acetonitrile
  • Suitable coupling agents include benzotriazo-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluoro phosphate (HBTU), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU), propane phosphonic acid anhydride (T3P) or 1,1′-carbonyldiimidazole (CDI) in a reaction inert solvent such as dichloromethane or dimethylformamide (DMF) in the presence of a base, such as triethylamine or diisopropyle
  • Intermediate (1c) may be prepared from Intermediate (1b) by removal of the protecting group.
  • the protecting group is t-butoxycarbonyl (BOC)
  • this may be removed by treatment with trifluoroacetic acid in a solvent such as methylene chloride at a temperature between about 0° C. to 30° C., typically ambient, for a period of about 10 minutes to 3 hours.
  • the BOC group may be removed by treatment with hydrogen chloride in a reaction inert solvent such as ethyl acetate, diethyl ether or dioxane at a temperature between about ⁇ 78° C. to 60° C. for a period of about 10 minutes to 24 hours.
  • the Cbz group may be removed by transfer hydrogenation in the presence of a suitable hydrogenation catalyst such as palladium on carbon or palladium hydroxide and ammonium formate in a reaction inert solvent such as ethyl acetate, methanol or ethanol at a temperature between 20° C. to 60° C., for a period of about 10 minutes to 24 hours.
  • a suitable hydrogenation catalyst such as palladium on carbon or palladium hydroxide and ammonium formate
  • a reaction inert solvent such as ethyl acetate, methanol or ethanol
  • the compounds of Formula (I) may be prepared from Intermediate (1c) by reductive amination with the desired indanone and a suitable reducing agent such as sodium borohydride, sodium triacetoxyborohydride, or sodium cyanoborohydride, in a suitable solvent such as THF, methylene chloride, dioxane or toluene.
  • a suitable reducing agent such as sodium borohydride, sodium triacetoxyborohydride, or sodium cyanoborohydride
  • a suitable solvent such as THF, methylene chloride, dioxane or toluene.
  • a base such as triethylamine or diisopropylethylamine to generate the free amine in situ.
  • the reaction proceeds via formation of an imine which may be facilitated by a dehydrating agent such as 4 ⁇ molecular sieves in toluene at a temperature between 20° C.
  • a titanium compound preferably titanium tetraisopropoxide may be employed, preferably in a reaction inert solvent such as dichloroethane or dichloromethane at room temperature.
  • a suitable polar solvent preferably ethanol
  • a suitable hydride reducing agent preferably sodium triacetoxyborohydride
  • the compounds of Formula (I) may be prepared from Intermediate (1e) by a Suzuki reaction with an aryl or heteroaryl compound R 2 -L-Lg (where L is typically a direct bond and Lg is an appropriate leaving group such as Cl, Br, I or triflate) in a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile in the presence of water, a suitable palladium catalyst such as palladium tetrakis(triphenylphosphine), 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride dichloromethane complex and a suitable base such as triethylamine, sodium carbonate, sodium bicarbonate or potassium acetate at a temperature between 25° C.
  • a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile
  • a suitable palladium catalyst such as palla
  • Intermediate (1e) may be prepared from Intermediate (1c) by reductive amination with 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-one using the conditions described above.
  • Intermediate (1e) may be prepared by first forming Intermediate (1d) via reductive amination of Intermediate (1c) with 5-bromo-indan-1-one using conditions described above.
  • the compounds of Formula (I) may be prepared from intermediate (1d) by a Suzuki reaction with an aryl compound R 2 B(OR) 2 where R is H or where both OR groups are taken together to form a pinacol group.
  • the coupling is conducted in a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile in the presence of water, a suitable palladium catalyst such as palladium tetrakis(triphenylphosphine), 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride dichloromethane complex and a suitable base such as triethylamine, sodium carbonate, sodium bicarbonate or potassium acetate at a temperature between about 25° C. and about 120° C., preferably between 100° C. and 120° C.
  • Reaction Scheme II depicts the synthesis of compounds within Formula (I) of Formula (I′) where L is a direct bond, Z, Z 1 and Z 2 are each CH and each Ra is hydrogen.
  • Intermediate (2b) may be prepared from Intermediate (2a) by reductive amination with the desired indanone and a suitable reducing agent such as those described above in Scheme I.
  • intermediate (2b) may be prepared from intermediate (2c), described below, by a Suzuki reaction with an aryl compound R 2 -L-Lg (where Lg is a leaving group) in a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile in the presence of water, a suitable palladium catalyst such as palladium tetrakis(triphenylphosphine), (1,1′-bis(diphenylphosphino)ferrocene palladium dichloride dichloromethane complex and a suitable base such as triethylamine, sodium carbonate, sodium bicarbonate or potassium acetate at a temperature between about 25° C. and about 125° C., preferably between 100° C. and 125° C.
  • a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile
  • a suitable palladium catalyst such as palla
  • the compounds of Formula (I′) may be prepared from Intermediate (2b) by a two step sequence. Firstly, the protecting group (Pg) is removed using the conditions described above. The amine intermediate is then reacted with a carboxylic acid of the formula R 1 CO 2 H (where R 1 is as described above) to give the desired compound of Formula (I) using the conditions described above in Scheme I.
  • compounds of Formula (I′) may be prepared by means of Intermediate (2c).
  • Intermediate (2c) may be prepared from Intermediate (2a) by reductive amination with (5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indan-1-one) using the conditions described above in Scheme I.
  • Intermediate (2e) may be prepared from Intermediate (2c) by a two step sequence. The protecting group (Pg) is first removed followed by the reaction of the free amine with a carboxylic acid of the formula R 1 CO 2 H (where R 1 is as described above). Intermediate (2e) may be converted to a compound of Formula (I′) using the conditions described above in Reaction Scheme I.
  • Intermediate (2c) may also be prepared from intermediate (2d) by borylation with (bispinacolato)diborane (also known as (4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl]) in a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile, preferably dioxane, in the presence of a suitable palladium catalyst such as 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride dichloromethane complex and a suitable base such as potassium acetate at a temperature between 25° C. and 120° C. preferably between 100° C. and 120° C.
  • Intermediate (2d) may be prepared from Intermediate (2a) by reductive amination with 5-bromo-indan-1-one and a suitable reducing agent using the conditions described above in Scheme I
  • the free amine can be reacted with di(tert-butyl)dicarbonate (Boc anhydride) in a reaction inert solvent such as dichloromethane at a temperature between ⁇ 10° C. to 30° C., preferably at ambient temperature.
  • a reaction inert solvent such as dichloromethane
  • Reaction Scheme III provides a specific route for the formation of enantiomeric compounds of Formula (I-A) (which are compounds of Formula (IA) in which L is a direct bond.
  • Intermediate (3b) or (3c) may be prepared from the aldehyde (3a) by reaction with (R)-5-bromo-indan-1-ylamine (SM-1: see, Scheme IV below) in a suitable solvent such as methanol or ethanol with a reducing agent such as sodium borohydride or sodium cyanoborohydride in the presence of an acid such as acetic acid at a temperature between about 0° C. and about 100° C., preferably between 30° C. and 80° C.
  • Intermediate (3d) may be prepared from Intermediate (3c) by a two step sequence.
  • the protecting group is first removed and the free amine is reacted with a carboxylic acid of formula R 1 CH 2 CO 2 H (where R 1 is as described herein). Suitable conditions are described in Scheme I above.
  • Intermediate (3e) may be prepared from Intermediate (3d) by borylation with (bispinacolato)diborane (also known as (4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl]) using the reaction conditions described above in Scheme I.
  • the compounds of Formula (1-A) may be prepared from Intermediate (3e) by a Suzuki reaction with an aryl compound R 2 -Lg (where Lg is an appropriate leaving group) as described above in Scheme I.
  • compounds of Formula (1-A) may be prepared using Intermediate (3b).
  • Intermediate (3b) may be prepared from the aldehyde (3a) by reaction with the desired indan-1-ylamine (SM-2) in a suitable solvent such as methanol or ethanol with a reducing agent such as sodium borohydride or sodium cyanoborohydride in the presence of an acid such as acetic acid at a temperature between 0° C. to 100° C., preferably between 30° C. and 80° C.
  • Intermediate (3b) may be prepared from Intermediate (3c) by a Suzuki reaction with an arylboronic acid of formula R 2 B(OR) 2 .
  • the coupling is generally conducted in a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile in the presence of water, a suitable palladium catalyst such as palladium tetrakis(triphenylphosphine), (1,1′-bis(diphenylphosphino)ferrocene palladium dichloride dichloromethane complex and a suitable base such as triethylamine, sodium carbonate, sodium bicarbonate or potassium acetate at a temperature between about 25° C. and 120° C., preferably between 100° C. and 120° C.
  • a reaction inert solvent such as dioxane, dimethoxyethane, toluene or acetonitrile
  • a suitable palladium catalyst such as palladium tetrakis(triphenylphosphine), (1,1′-bis(diphenylphosphino)ferrocene palladium dich
  • Intermediate (3b) may be prepared from intermediate (3c) via an in situ borylation (with (bispinacolato)diborane using the reaction conditions described above in Reaction Scheme I) followed by a Suzuki reaction with an aryl compound R 2 -L (where L is a leaving group such as Cl, Br, I or triflate) using the reaction conditions described above in Reaction Scheme I).
  • Compounds of Formula (I-A) may be prepared from intermediate (3b) by first removing the protecting group followed by reaction with a carboxylic acid of the formula R 1 CH 2 CO 2 H (where R 1 is as described herein) using the conditions described in Reaction Scheme I.
  • Scheme IV describes the synthesis of the enantioenriched indanyl amines used in Scheme III above from commercially available 5-bromo-indan-1-one.
  • Starting materials SM-1 and SM-2 may be prepared from the alcohols (4a) and (4e) respectively by a series of transformations involving inversion of the stereochemistry at the chiral center.
  • the alcohol is treated with diphenyl phosphorazidate (DPPA) in a reaction inert solvent such as dichloromethane, 2-methyltetrahydrofuran or toluene in the presence of a base, such as DBU, at a temperature between about ⁇ 10° C. and about 30° C., preferably ambient, to produce the azidoindane intermediate of opposite stereochemistry.
  • DPPA diphenyl phosphorazidate
  • the azide may be prepared from the alcohols (4a) and (4e) by conversion of the alcohol to a leaving group such as mesylate, tosylate or triflate followed by treatment with an azide such as sodium azide in a reaction inert solvent such as DMF, DMSO, acetonitrile or acetone using procedures well known to those skilled in the art for example as described in L. A. Paquette (Ed), Encyclopedia of Reagents for Organic Synthesis , John Wiley and Sons, Chichester, England, 1995.
  • a leaving group such as mesylate, tosylate or triflate
  • an azide such as sodium azide in a reaction inert solvent such as DMF, DMSO, acetonitrile or acetone
  • the azide is then reduced to the corresponding amine by treatment with a phosphine, such as triphenylphosphine or trimethylphosphine followed by aqueous hydrolysis at a temperature between about ⁇ 10° C. and about 30° C., preferably at ambient temperature.
  • a phosphine such as triphenylphosphine or trimethylphosphine
  • the azide may be reduced by treatment with tin(II) chloride in a reaction inert solvent such as methanol or toluene or a mixture thereof at a temperature between about 20° C. and about 60° C., preferably at about 23° C., for a period of about 10 minutes to 24 hours.
  • the azide may be reduced by hydrogenation in the presence of a suitable hydrogenation catalyst such as palladium on carbon or palladium hydroxide in a reaction inert solvent such as ethyl acetate, methanol or ethanol at a temperature between about 20° C. and about 60° C., preferably at ambient temperature, for a period of about 10 minutes to 24 hours.
  • a suitable hydrogenation catalyst such as palladium on carbon or palladium hydroxide
  • a reaction inert solvent such as ethyl acetate, methanol or ethanol
  • Alcohols (4a) and (4e) may be prepared by reduction of 5-bromo-indan-1-one and ketone (4d), respectively, using an enantioselective reduction procedure.
  • the preferred procedure uses borane-methyl sulfide complex in the presence of the catalyst R-(+)-2-Methyl-CBS-oxazaborolidine (also known as (3aR)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole) in a reaction inert solvent such as tetrahydrofuran at a temperature between ⁇ 10° C. and 0° C.
  • R-(+)-2-Methyl-CBS-oxazaborolidine also known as (3aR)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole
  • reaction inert solvent
  • Intermediate (5b) may be prepared from Intermediate (3c) by a Suzuki reaction with carbamoyl-aryl-B(OR) 2 or carbamoyl-heteroaryl-B(OR) 2 (where carbamoyl-aryl and carbamoyl-heteroaryl are within the definition of R 2 as provided herein) using the reaction conditions described above in Reaction Scheme I.
  • Intermediate (5b) may be prepared from Intermediate (5a) by hydration of the cyano group in a suitable solvent such as water, with a reducing agent such as urea-hydrogen peroxide, in the presence of base such as sodium hydroxide at a temperature between 0° C. and 30° C., preferably at about 23° C., for a period of about 10 minutes to 24 hours.
  • Intermediate (5c) may be prepared from Intermediate (5a) by a two step sequence. The protecting group is first removed and then the free amine is reacted with a carboxylic acid of the formula R 1 CH 2 CO 2 H (where R 1 is as described herein). Suitable conditions are described in Scheme I above.
  • Intermediate (5a) may be prepared from Intermediate (3c) (Scheme III above) by a Suzuki reaction with cyano-aryl-B(OR) 2 or cyano-heteroaryl-B(OR) 2 (where the cyano-aryl and cyano-heteroaryl are within the definition of R 2 as provided herein).
  • Intermediate (5a) may be prepared from Intermediate (3c) via an in situ borylation (with (bispinacolato)diborane using the reaction conditions described above in Scheme I) followed by a Suzuki reaction with cyano-aryl-Lg or cyano-heteroaryl-Lg (where Lg is a leaving group such as Cl, Br, I or triflate and cyano-aryl and cyano-heteroaryl are defined as above) using the reaction conditions described above.
  • Compounds of formula (1-B) may be prepared from Intermediate (5b) by a two step sequence. The protecting group is first removed and the free amine is reacted with a carboxylic acid of the formula R 1 CH 2 CO 2 H (where R 1 is as described above). Suitable conditions are described in Scheme I above. Alternatively, compounds of formula (1-B) may be prepared from Intermediate (5c) by hydrolysis of the cyano group using the reaction conditions described above.
  • Intermediate (5d) may be prepared by treatment of Intermediate (3b) (as prepared above in Scheme III) with an optionally substituted isochroman-1,3-dione (where R is an appropriate substituent as provided within the definition of R 1 ) in a suitable solvent such as acetonitrile, in the presence of base such as triethylamine at a temperature between 0° C. and 80° C., preferably 23° C., for a period of about 10 minutes to 24 hours.
  • a suitable solvent such as acetonitrile
  • Compounds of formula (1-C) may be prepared by an aminolysis of Intermediate (5d) with an amine of formula R x NHR y (where R x and R y are an appropriate group as provided for in the definition of R 1 ) using the conditions described above in Scheme 1.
  • Intermediate (5d) may be prepared from Intermediate (3b) by a two-step sequence. The protecting group is first removed and the free amine is reacted with a homophthalide derivative (wherein R is methyl or methoxyl) in a reaction inert solvent such as acetonitrile and in the presence of a base such as triethylamine at a temperature between 0° C. and 50° C., preferably room temperature, for a period of about 10 minutes to 24 hours.
  • a homophthalide derivative wherein R is methyl or methoxyl
  • a reaction inert solvent such as acetonitrile
  • a base such as triethylamine
  • Reaction Scheme VI provides a further reaction scheme which depicts the preparation of compounds within Formula I wherein R 1 is -L 1 -R 1′ .
  • Compounds of formula (II-a) may be prepared from Intermediate (3b) by a two step sequence. The protecting group is first removed and the free amine is reacted with a carboxylic acid of the formula R 1′ L 1 CH 2 CO 2 H (where R 1 is as described above). Suitable conditions are described in Scheme I above.
  • Compounds of formula (II-B) may be prepared from compounds IIa by transformation of key functional groups, e.g hydrolysis of nitrile to amide.
  • Intermediate (6b) may be prepared by treatment of Intermediate (3b) (as prepared above in Scheme III) with an optionally substituted diacid 6a (where R is an appropriate substituent as provided within the definition of R 1 ) in a suitable solvent such as dichloromethane in the presence of base such as triethylamine using an amide coupling reagent such as 1,1′-carbonyldiimidazole.
  • the compounds of the present invention may be isolated and used per se, or when possible, in the form of its pharmaceutically acceptable salt.
  • salts refers to inorganic and organic salts of a compound of the present invention. These salts can be prepared in situ during the final isolation and purification of a compound, or by separately reacting the compound with a suitable organic or inorganic acid or base and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, hydroiodide, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, besylate, palmitiate, pamoate, malonate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, hexafluorophosphate, benzene sulfonate, tosylate, formate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like.
  • alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
  • non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. See, e.g., Berge, et al., J. Pharm. Sci. 66, 1-19 (1977).
  • the compounds of the present invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. Unless specified otherwise, it is intended that all stereoisomeric forms of the compounds of the present invention as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the present invention incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column. Alternatively, the specific stereoisomers may be synthesized by using an optically active starting material, by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one stereoisomer into the other by asymmetric transformation.
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations.
  • a specific example of a proton tautomer is the imidazole moiety where the proton may migrate between the two ring nitrogens.
  • Valence tautomers include interconversions by reorganization of some of the bonding electrons.
  • Certain compounds of the present invention may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example, because of steric hindrance or ring strain, may permit separation of different conformers.
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, respectively.
  • Certain isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Positron emitting isotopes such as 15 O, 13 N, 11 C, and 18 F are useful for positron emission tomography (PET) studies to examine substrate occupancy.
  • Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • Certain compounds of the present invention may exist in more than one crystal form (generally referred to as “polymorphs”).
  • Polymorphs may be prepared by crystallization under various conditions, for example, using different solvents or different solvent mixtures for recrystallization; crystallization at different temperatures; and/or various modes of cooling, ranging from very fast to very slow cooling during crystallization. Polymorphs may also be obtained by heating or melting the compound of the present invention followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning colorimetry, powder X-ray diffraction or such other techniques.
  • Compounds of the present invention are useful for treating diseases, conditions and/or disorders that are mediated by the antagonism or inverse agonism of the ghrelin receptor; therefore, another embodiment of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable excipient, diluent or carrier.
  • the compounds of the present invention (including the compositions and processes used therein) may also be used in the manufacture of a medicament for the therapeutic applications described herein.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier, diluent or excipient.
  • Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
  • the particular carrier, diluent or excipient used will depend upon the means and purpose for which the compound of the present invention is being applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal.
  • GRAS solvents recognized by persons skilled in the art as safe
  • safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water.
  • Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), etc. and mixtures thereof.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • buffers stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • the formulations may be prepared using conventional dissolution and mixing procedures.
  • the bulk drug substance i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)
  • a suitable solvent in the presence of one or more of the excipients described above.
  • the compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product.
  • the pharmaceutical compositions also include solvates and hydrates of the compounds of Formula (I).
  • solvate refers to a molecular complex of a compound represented by Formula (I) (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, ethylene glycol, and the like
  • hydrate refers to the complex where the solvent molecule is water.
  • the solvates and/or hydrates preferably exist in crystalline form.
  • solvents may be used as intermediate solvates in the preparation of more desirable solvates, such as methanol, methyl tert-butyl ether, ethyl acetate, methyl acetate, (S)-propylene glycol, (R)-propylene glycol, 1,4-butyne-diol, and the like.
  • the pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug.
  • an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form.
  • Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like.
  • the container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package.
  • the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
  • the present invention further provides a method of treating diseases, conditions and/or disorders mediated by the antagonism of the ghrelin receptor in an animal that includes administering to an animal in need of such treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition comprising an effective amount of a compound of the present invention and a pharmaceutically acceptable excipient, diluent, or carrier.
  • One aspect of the present invention is the treatment of obesity, and obesity-related disorders (e.g., overweight, weight gain, or weight maintenance).
  • obesity-related disorders e.g., overweight, weight gain, or weight maintenance.
  • BMI body mass index
  • Overweight is typically defined as a BMI of 25-29.9 kg/m 2
  • obesity is typically defined as a BMI of 30 kg/m 2 .
  • Another aspect of the present invention is for the treatment or delaying the progression or onset of diabetes or diabetes-related disorders including type 1 (insulin-dependent diabetes mellitus, also referred to as “IDDM”) and type 2 (noninsulin-dependent diabetes mellitus, also referred to as “NIDDM”) diabetes, impaired glucose tolerance, insulin resistance, hyperglycemia, and diabetic complications (such as atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy, hypertension, neuropathy, and retinopathy).
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM noninsulin-dependent diabetes mellitus
  • impaired glucose tolerance such as atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy, hypertension, neuropathy, and retinopathy.
  • Metabolic syndrome includes diseases, conditions or disorders such as dyslipidemia, hypertension, insulin resistance, diabetes (e.g., type 2 diabetes), weight gain, coronary artery disease and heart failure.
  • diseases, conditions or disorders such as dyslipidemia, hypertension, insulin resistance, diabetes (e.g., type 2 diabetes), weight gain, coronary artery disease and heart failure.
  • Metabolic Syndrome see, e.g., Zimmet, P. Z., et al., “The Metabolic Syndrome: Perhaps an Etiologic Mystery but Far From a Myth—Where Does the International Diabetes Federation Stand?,” Diabetes & Endocrinology, 7(2), (2005); and Alberti, K. G., et al., “The Metabolic Syndrome—A New Worldwide Definition,” Lancet, 366, 1059-62 (2005).
  • administration of the compounds of the present invention provides a statistically significant (p ⁇ 0.05) reduction in at least one cardiovascular disease risk factor, such as lowering of plasma leptin, C-reactive protein (CRP) and/or cholesterol, as compared to a vehicle control containing no drug.
  • cardiovascular disease risk factor such as lowering of plasma leptin, C-reactive protein (CRP) and/or cholesterol
  • the administration of compounds of the present invention may also provide a statistically significant (p ⁇ 0.05) reduction in glucose serum levels.
  • the present invention also relates to therapeutic methods for treating the above described conditions in a mammal, including a human, wherein a compound of Formula (I) of this invention is administered as part of an appropriate dosage regimen designed to obtain the benefits of the therapy.
  • the appropriate dosage regimen, the amount of each dose administered and the intervals between doses of the compound will depend upon the compound of Formula (I) of this invention being used, the type of pharmaceutical compositions being used, the characteristics of the subject being treated and the severity of the conditions.
  • an effective dosage for the compounds of the present invention is in the range of 0.01 mg/kg/day to 30 mg/kg/day, preferably 0.01 mg/kg/day to 5 mg/kg/day of active compound in single or divided doses.
  • some variability in the general dosage range may be required depending upon the age and weight of the subject being treated, the intended route of administration, the particular compound being administered and the like.
  • the determination of dosage ranges and optimal dosages for a particular patient is well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure. Practitioners will appreciate that “kg” refers to the weight of the patient measured in kilograms.
  • the compounds or compositions of this invention may be administered in single (e.g., once daily) or multiple doses or via constant infusion.
  • the compounds of this invention may also be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses.
  • suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • compositions of the present invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally, (e.g., intravenously, subcutaneously or intramedullary). Further, the pharmaceutical compositions of this invention may be administered intranasally, as a suppository, or using a “flash” formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.
  • the compounds of the present invention can be used in sustained release, controlled release, and delayed release formulations, which forms are also well known to one of ordinary skill in the art.
  • the compounds of this invention may also be used in conjunction with other pharmaceutical agents for the treatment of the diseases, conditions and/or disorders described herein. Therefore, methods of treatment that include administering compounds of the present invention in combination with other pharmaceutical agents are also provided.
  • Suitable pharmaceutical agents that may be used in combination with the compounds of the present invention include anti-obesity agents (including appetite suppressants), anti-diabetic agents, anti-hyperglycemic agents, lipid lowering agents, and anti-hypertensive agents.
  • Suitable lipid lowering agents that can be combined with the compounds of the present invention include, for example, those described at page 30, line 20 through page 31, line 30 of WO 2011005611.
  • the lipid lowering agents include bile acid sequestrants, HMG-CoA reductase inhibitors, HMG-CoA synthase inhibitors, cholesterol absorption inhibitors, acyl coenzyme A-cholesterol acyl transferase (ACAT) inhibitors, CETP inhibitors, squalene synthetase inhibitors, PPAR ⁇ agonists, FXR receptor modulators, LXR receptor modulators, lipoprotein synthesis inhibitors, rennin angiotensisn system inhibitors, PPAR ⁇ partial agonists, bile acid reabsorption inhibitors, PPAR ⁇ agonists, triglyceride synthesis inhibitors, microsomal triglyceride transport inhibitors, transcription modulators, squalene epoxidase inhibitors,
  • Suitable anti-hypertensive agents that can be combined with the compounds of the present invention include, for example, those described at page 31, line 31 through page 32, line 18 of WO 2011005611.
  • the anti-hypertensive agents include diuretics, beta-adrenergic blockers, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, neutral endopeptidase inhibitors, endothelin antagonists, vasodilators, angiotensin II receptor antagonists, ⁇ / ⁇ adrenergic blockers, alpha 1 blockers, alpha 2 agonists, aldosterone inhibitors, mineraocorticoid receptor inhibitors, renin inhibitors and angiopoietin-2-binding agents.
  • ACE angiotensin converting enzyme
  • Suitable anti-diabetic agents include an acetyl-CoA carboxylase-(ACC) inhibitor such as those described in WO2009144554, WO2003072197, WO2009144555 and WO2008065508, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, such as those described in WO09016462 or WO2010086820, AZD7687 or LCQ908, diacylglycerol O-acyltransferase 2 (DGAT-2) inhibitor, monoacylglycerol O-acyltransferase inhibitors, a phosphodiesterase (PDE)-10 inhibitor, an AMPK activator, a sulfonylurea (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone,
  • GSK1362885 a VPAC2 receptor agonist
  • SGLT2 inhibitors such as those described in E. C. Chao et al. Nature Reviews Drug Discovery 9, 551-559 (July 2010) including dapagliflozin, canagliflozin, BI-10733, tofogliflozin (CSG452), ASP-1941, THR1474, TS-071, ISIS388626 and LX4211 as well as those in WO2010023594, a glucagon receptor modulator such as those described in Demong, D. E. et al.
  • GPR119 modulators particularly agonists, such as those described in WO2010140092, WO2010128425, WO2010128414, WO2010106457, Jones, R. M. et al. in Medicinal Chemistry 2009, 44, 149-170 (e.g. MBX-2982, GSK1292263, APD597 and PSN821), FGF21 derivatives or analogs such as those described in Kharitonenkov, A. et al.
  • TGR5 also termed GPBAR1 receptor modulators, particularly agonists, such as those described in Zhong, M., Current Topics in Medicinal Chemistry, 2010, 10(4), 386-396 and INT777, GPR40 agonists, such as those described in Medina, J. C., Annual Reports in Medicinal Chemistry, 2008, 43, 75-85, including but not limited to TAK-875, GPR120 modulators, particularly agonists, high affinity nicotinic acid receptor (HM74A) activators, and SGLT1 inhibitors, such as GSK1614235.
  • HM74A high affinity nicotinic acid receptor
  • anti-diabetic agents that can be combined with the compounds of the present invention can be found, for example, at page 28, line 35 through page 30, line 19 of WO2011005611.
  • Preferred anti-diabetic agents are metformin and DPP-IV inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin and saxagliptin).
  • antidiabetic agents could include inhibitors or modulators of carnitine palmitoyl transferase enzymes, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 and/or CCR5, inhibitors of PKC isoforms (e.g.
  • suitable anti-diabetic agents include mechanisms listed by Carpino, P. A., Goodwin, B. Expert Opin. Ther. Pat, 2010, 20(12), 1627-51.
  • Suitable anti-obesity agents include 11 ⁇ -hydroxy steroid dehydrogenase-1 (11 ⁇ -HSD type 1) inhibitors, stearoyl-CoA desaturase-1 (SCD-1) inhibitor, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors (such as sibutramine), sympathomimetic agents, ⁇ 3 adrenergic agonists, dopamine agonists (such as bromocriptine), melanocyte-stimulating hormone analogs, 5HT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e.
  • anorectic agents such as a bombesin agonist
  • neuropeptide-Y antagonists e.g., NPY Y5 antagonists such as velneperit
  • PYY 3-36 including analogs thereof
  • BRS3 modulator mixed antagonists of opiod receptor subtypes, thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid agonists or antagonists, orexin antagonists, glucagon-like peptide-1 agonists, ciliary neurotrophic factors (such as AxokineTM available from Regeneron Pharmaceuticals, Inc., Tarrytown, N.Y.
  • AxokineTM available from Regeneron Pharmaceuticals, Inc., Tarrytown, N.Y.
  • GTP/ApoB inhibitors e.g., gut-selective MTP inhibitors, such as dirlotapide, JTT130, Usistapide, SLx4090
  • opioid antagonist e.g., mu opioid receptor modulators, including but not limited to GSK1521498, MetAp2 inhibitors, including but not limited to ZGN-433, agents with mixed modulatory activity at 2 or more of glucagon, GIP and GLP1 receptors, such as MAR-701 or ZP2929, norepinephrine transporter inhibitors, cannabinoid-1-receptor antagonist/inverse agonists, ghrelin agonists/antagonists, oxyntomodulin and analogs, monoamine uptake inhibitors, such as but not limited to tesofensine, an orexin antagonist, combination agents (such as
  • Preferred anti-obesity agents for use in the combination aspects of the present invention include gut-selective MTP inhibitors (e.g., dirlotapide, mitratapide and implitapide, R56918 (CAS No. 403987) and CAS No. 913541-47-6), CCKa agonists (e.g., N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza-benzo[e]azulen-6-yl]-N-isopropyl-acetamide described in PCT Publication No. WO 2005/116034 or US Publication No.
  • CCKa agonists e.g., N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza
  • PYY 3-36 includes analogs, such as peglated PYY 3-36 e.g., those described in US Publication 2006/0178501), opioid antagonists (e.g., naltrexone), oleoyl-estrone (CAS No.
  • compounds of the present invention and combination therapies are administered in conjunction with exercise and a sensible diet.
  • starting materials are generally available from commercial sources such as Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, N.H.), Acros Organics (Fairlawn, N.J.), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, N.J.), and AstraZeneca Pharmaceuticals (London, England).
  • NMR spectra were recorded on a Varian UnityTM 400 (available from Varian Inc., Palo Alto, Calif.) at room temperature at 400 and 500 MHz 1H, respectively. Chemical shifts are expressed in parts per million ( ⁇ ) relative to residual solvent as an internal reference.
  • the peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet; v br s, very broad singlet; br m, broad multiplet. In some cases only representative 1 H NMR peaks are given.
  • Mass spectra were recorded by direct flow analysis using positive and negative atmospheric pressure chemical ionization (APcI) scan modes.
  • a Waters APcI/MS model ZMD mass spectrometer equipped with Gilson 215 liquid handling system was used to carry out the experiments.
  • Mass spectrometry analysis was also obtained by RP-HPLC gradient method for chromatographic separation. Molecular weight identification was recorded by positive and negative electrospray ionization (ESI) scan modes.
  • ESI electrospray ionization
  • a Waters/Micromass ESI/MS model ZMD or LCZ mass spectrometer (Waters Corp., Milford, Mass.) equipped with Gilson 215 liquid handling system (Gilson, Inc., Middleton, Wis.) and HP 1100 DAD (Hewlett Packard) was used to carry out the experiments.
  • references to “enantiomer 1” or “enantiomer 2” merely refer to the order in which the compounds elute from the column and do not imply a relative absolute stereochemistry.
  • Celite® is a registered trademark for a form of diatomaceous earth available from J T Baker, Phillipsburg, N.J.
  • the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (150 mL) and water (200 mL). A dark, nearly black, mixture formed.
  • the mixture was filtered through a plug of Celite® with an ethyl acetate rinse. The mixture was transferred to a separation funnel. The organic phase was separated and the aqueous layer was washed with ethyl acetate (2 ⁇ 50 mL). The combined organic solutions were washed with brine, dried over anhydrous MgSO 4 and decolorized with charcoal while warm. Filtration and solvent removal afforded 14.5 g of a brown sticky solid. This solid was triturated with a diethyl ether/heptanes mixture.
  • the reaction was concentrated to dryness and was partitioned between ethyl acetate and water. The water layer was extracted with ethyl acetate and the combined organic layers were washed twice with water and once with brine. The solution was dried over anhydrous sodium sulfate, filtered and concentrated. The final product was purified by silica chromatography on a Combiflash ISCO purification system (Teledyne Corp., Lincoln, Nebr.) eluting with 0-50% ethyl acetate in heptanes. The product was obtained as a white solid (SM-1e, 8.7 mg, 20%). MS (ES+) 225.2 (M+H + ).
  • the crude tert-butyl cyano(5-methoxypyridin-2-yl)acetate (3.46 g) was suspended in a mixture of 45 mL of water and 45 mL of concentrated HCl. The mixture was heated at 60° C. for 1 hour and at reflux overnight. The reaction was cooled and the water was removed under vacuum. The oily solid residue was redissolved in a minimal amount of water ( ⁇ 50-70 mL) and 2N NaOH was added to adjust the pH to approximately 14. The solution was washed with diethyl ether and was reacidified to pH 4 with 2N HCl and concentrated to dryness to give a white solid.
  • (5-Methylpyridin-2-yl)acetic acid was prepared using analogous procedures to those used for the preparation of (5-methoxypyridin-2-yl)acetic acid (SM-1ab) substituting 2-bromo-5-methylpyridine for 2-bromo-5-methoxypyridine.
  • the crude (5-bromo-pyridin-2-yl)-cyano-acetic acid tert-butyl ester (20.1 g) was dissolved in anhydrous THF (300 mL) and the dark red solution was cooled in an ice-water bath. After purging in a stream of nitrogen, diethylzinc (88.0 mL, 88.0 mmol, 1M in hexane) was slowly added over 50 minutes. The internal temperature was maintained below 4° C. The catalyst 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride-CH 2 Cl 2 (1:1 complex) (1.61 g, 1.97 mmol) was added and the mixture was heated at 50° C. for 35 minutes.
  • Cyano-(5-ethyl-pyridin-2-yl)-acetic acid tert-butyl ester (7.3 g) was mixed with 70 mL of water and 70 mL of 12N HCl and was heated at 104° C. for 3 hours before removing the volatiles in vacuo. Water was added to dissolve the solids and the pH of the solution was adjusted to 9-10 with 2N NaOH. The solution was washed with 2-methylTHF (2 ⁇ ). The aqueous solution was adjusted to pH 4 with 2N HCl and was concentrated under vacuum to an oily solid.
  • Ethyl(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetate hydrobromide (226 g, 0.74 mol) was dissolved in water (350 mL) and the solution was adjusted to pH 7 by addition of potassium carbonate (51.0 g, 0.37 mol). The aqueous solution was extracted with methylene chloride (300 mL) and the organic phase was washed with brine (150 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give ethyl (2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetate as a brown oil (151.3 g).
  • the crude product was purified by Combiflash (Teledyne ISCO, Lincoln, Nebr.) chromatography using 0-100% EtOAc/heptanes. Both the desired product and (2-methyl-imidazo[2,1-b][1,3,4]thiadiazol-6-ylyacetic acid methyl ester (formed by trans esterification with solvent MeOH) were obtained with a total mass of 333 mg (54%). The crude mixture was used directly in the next step
  • Methyl(4-cyclopropylphenyl)acetate (710 mg, 3.73 mmol) was dissolved in 5 mL THF, 5 mL MeOH, and aqueous 1N NaOH (7.46 mmol) and the resulting mixture was heated at 45° C. overnight. After cooling to ambient temperature, the reaction was concentrated in vacuo and the residue was diluted with water (50 mL). The aqueous material was acidified with 1N HCl to pH ⁇ 3. A light brown precipitate formed which was collected by filtration and dried in a vacuum oven for 3 days to give (4-cyclopropylphenyl)acetic acid (SM-1ag, 395 mg, 60%). MS (ES ⁇ ) 175.2 (M ⁇ H).
  • the (2-cyano-4-methoxy-phenyl)-acetic acid methyl ester 120 mg, 0.585 mmol was dissolved in 10 mL THF and 2 mL water and LiOH monohydrate (101 mg, 2.34 mmol) was added. The mixture was heated at 55° C. overnight. The mixture was cooled to room temperature and the solvent was removed in vacuo. The residue was dissolved in 30 mL water and adjusted to pH ⁇ 14 with aqueous 1N NaOH. The aqueous layer was washed with 50 mL of ethyl acetate. The organic extract was discarded and the aqueous phase was treated with 1N HCl (aq.) to pH ⁇ 2-3.
  • Ethyl cyanoacetate (2.56 mL, 24.0 mmol) was added dropwise to a suspension of 959 mg of NaH (60%, 24.0 mmol) in 10 mL of DMF. The mixture was stirred for 1 h at room temperature. CsF (61 mg, 0.4 mmol) and a solution of 4-chloro-3-nitro-anisole (1.5 g, 8.0 mmol) in 2 mL of DMF were added and the mixture was stirred overnight at 70° C. The reaction mixture was cooled to room temperature and was quenched by the addition of 5 mL of water. Aqueous 1N HCl (5 mL) was added to adjust the pH to 3-4 and the mixture was diluted with dichloromethane.
  • Methyl 2-(2-methoxy-2-oxoethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (42.0 mg, 0.17 mmol), as prepared according to the procedure described in Stefan Löber, S.; Hübner, H.; Gmeiner B.; Biorg. Med. Chem. Lett. 12(17), 2377 (2002), was dissolved in MeOH (5 mL) and was hydrogenated on an H-Cube® hydrogenation apparatus with 10% Pd/C at 40° C. for 1 hour.
  • Chloroiodomethane (17.9 mL, 239 mmol) was added dropwise and the mixture was stirred for 1 h. The mixture was quenched with 250 mL of saturated aqueous NaHCO 3 followed by extraction with ethyl acetate (3 ⁇ 250 mL).
  • tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate hydrochloride (1.89 g, 7.18 mmol) in anhydrous dichloromethane (50 mL).
  • Triethylamine (2 mL, 14.4 mmol) followed by 5-methoxypyridin-2-yl)acetic acid (SM-1aa, 1.2 g, 7.18 mmol) were added.
  • HATU (3.28 g, 8.62 mmol) was added and the resulting bright yellow solution was stirred at room temperature for 15 hours.
  • the reaction was heated under nitrogen at 110° C. for 5 hours. After consumption of the starting material (as monitored by TLC), the reaction was cooled to room temperature and 2-chloro-pyrimidine (71.0 mg, 0.63 mmol), Pd(dppf)Cl 2 (15 mg, 0.02 mmol) and aqueous K 2 CO 3 solution (2M, 2.25 mL, de-oxygenated with nitrogen for 15 minutes prior to addition) were added. The reaction was purged with nitrogen (3 ⁇ ) and heated under nitrogen for 20 hours at 110° C. The reaction was cooled to room temperature and was filtered through a short plug of silica gel, eluting with methanol.
  • the organic layer was extracted to an aqueous solution containing 1.5 equiv of HCl (40 mL). The organic layer was removed and the resulting solution was treated with (4 g) ISOLUTE® Ultra Pure Si-Thiol silica gel for 1.5 hours and filtered. The aqueous solution was adjusted to pH 7.8 with 4N NaOH and extracted with toluene (40 mL). The toluene layer was concentrated to approximately 15 mL under vacuum at 45° C. and heptane (75 mL) was added slowly and the mixture was stirred at 20° C. for 1 hour. The product was filtered and dried under vacuum at 45° C.
  • the organic layer was charged with water (200 mL) and the layer was acidified to pH 2.5 with 1 N HCl. The resulting mixture was filtered, the layers were separated and the aqueous layer was adjusted to pH 7.8 with 4 N K 2 CO 3 and extracted with dichloromethane. The solution was treated with ISOLUTEO Ultra Pure Si-Thiol silica gel for 1 h, followed by filtration. The filtrate was concentrated under reduced pressure to give a viscous oil (24.0 g) that was carried forward to the following step without further purification.
  • the reaction mixture was concentrated under reduced pressure and the residual DMF was azeotroped with toluene.
  • the residue was partitioned between 50 mL of ethyl acetate and 50 mL 1N NaOH solution.
  • the organic layer was collected, washed with saturated brine, dried over Na 2 SO 4 and concentrated.
  • the crude product was purified on an Analogix (Analogix Inc., Burlington, Wis.) 8 g silica column (1-10% MeOH in CH 2 Cl 2 in 20 minutes) to afford the desired product (554 mg, 79.4%) as an off-white foam.
  • the organic layer was concentrated to remove dichloromethane while replacing with isopropanol to a volume of approximately 70 mL at atmospheric pressure until 81° C. was achieved.
  • the temperature was lowered to 50° C. and held for crystallization. After solids were formed, the temperature was adjusted down to 10° C. at 0.2° C./min (2.5 hours) and held for 1 h.
  • the solid was then filtered and the filter cake was washed with isopropanol and the product was dried under vacuum at 45° C. for 8 h to obtain the desired product 3F as an off white powder (4.73 g, 79%).
  • a 5 L reactor equipped with a mechanical stirrer, nitrogen line and condenser was charged with the aforementioned material (200 g, 389.4 mmol) followed by ethanol (2 L). The resulting mixture was then heated to 70° C. and stirred for at least 10 min.
  • fumaric acid 51.97 g, 447.8 mmol
  • the resulting mixture was stirred until dissolved and the two ethanolic solutions were mixed, maintaining pot temperature >65° C.
  • the resulting solution was then stirred for 1 h at 70° C. under nitrogen while stirring. This was then cooled at 0.2° C. per min to 55° C., held at 55° C.
  • Triethylamine (0.1 mL) was added to a solution of 2-(5-pyrimidin-2-yl-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonane dihydrochloride (5-1b, 80 mg, 0.2 mmol), 4-cyclopropylphenylacetic acid (SM-1ag, 31 mg, 0.2 mmol), and HATU (93 mg, 0.24 mmol) in dichloromethane (5 mL) in a vial. The reaction was stirred at room temperature overnight and was quenched with aqueous sodium bicarbonate. The organic layer was dried over MgSO 4 , filtered and concentrated.
  • SM-1ag 4-cyclopropylphenylacetic acid
  • HATU 93 mg, 0.24 mmol
  • the racemic mixture (5A) was separated on a chiral column (Chiralcel OD-H, 250 mm ⁇ 30 mm, Flow-rate—100 g/min, 65/35 CO 2 /MeOH, with 0.1% IPA) to afford the title compound (19 mg) as a white powder.
  • GHSR growth hormone secretagogue receptor
  • IC 50 inhibitory concentration to decrease activity by 50%
  • K i IC 50 /(1+[ligand]/Kd)
  • HEK293 Human Embryonic Kidney 293 cells
  • GTP guanosine triphosphate
  • PEI polyethyleneimine
  • test compounds in the present invention To measure the ability of test compounds in the present invention to bind to the ghrelin receptor, and therefore have the potential to modulate ghrelin activity, radioligand displacement assays are performed.
  • the SPA format was utilized for high throughput screening of test compounds and filter binding served for more comprehensive binding characterization.
  • test compound affinity is expressed as K i value, defined as the concentration of compound required to decrease [ 125 I] ghrelin binding by 50% for a specific membrane batch at a given concentration of radioligand.
  • Ghrelin SPA binding assays are performed in a final volume of 90 ⁇ l containing 250 ng human GHSR1a (HEK293 Tetracycline-Inducible cell line expressing the human growth secretagogue receptor 1a; prepared as membranes) coupled to 0.5 mg SPA beads (wheat germ agglutinin coated, GE Healthcare, RPNQ0060) and 50 ⁇ M [ 125 I] ghrelin (Perkin Elmer Life Sciences, NEX-388), plus varying concentrations of test compound or vehicle.
  • human GHSR1a HEK293 Tetracycline-Inducible cell line expressing the human growth secretagogue receptor 1a; prepared as membranes
  • 0.5 mg SPA beads wheat germ agglutinin coated, GE Healthcare, RPNQ0060
  • 50 ⁇ M [ 125 I] ghrelin Perkin Elmer Life Sciences, NEX-388
  • assays are prepared at room temperature in 384-well plates (Matrix, 4322) containing 2 ⁇ l of test compound in DMSO (or DMSO as vehicle). Assays are initiated by addition of 28 ⁇ l assay buffer (50 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, EDTA-free protease inhibitors—1 tablet/50 ml buffer, pH 7.4), 30 ⁇ l 8.3 ⁇ g/ml hGHSR1a membrane and 30 ⁇ l of 150 pM [ 125 I] ghrelin, both in assay buffer.
  • assay buffer 50 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, EDTA-free protease inhibitors—1 tablet/50 ml buffer, pH 7.4
  • 30 ⁇ l 8.3 ⁇ g/ml hGHSR1a membrane 30 ⁇ l of 150 pM [ 125 I] ghrelin, both in assay buffer
  • the mixture is incubated for 8 hours to allow binding to reach equilibrium and the amount of receptor-ligand complex is determined by liquid scintillation counting using a 1450 Microbeta Trilux (Wallac).
  • Ghrelin binding assays are performed in a final volume of 100 ⁇ l containing 100 ng human GHSR1a (HEK293 Tetracycline-Inducible cell line expressing the human growth secretagogue receptor 1a; prepared as membranes) and 50 pM [ 125 I] ghrelin (Perkin Elmer Life Sciences, NEX-388), plus varying concentrations of test compound or vehicle.
  • human GHSR1a HEK293 Tetracycline-Inducible cell line expressing the human growth secretagogue receptor 1a; prepared as membranes
  • 50 pM [ 125 I] ghrelin Perkin Elmer Life Sciences, NEX-388
  • assays are prepared at room temperature in 96-well plates (Costar, 3357) containing 2 ⁇ l of test compound in DMSO (or DMSO as vehicle). Assays are initiated by addition of 23 ⁇ l assay buffer (50 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, EDTA-free protease inhibitor tablets—1 tablet/50 ml buffer, pH 7.4), 25 ⁇ g/ml hGHSR1a membrane and 50 ⁇ l of 100 ⁇ M [ 125 I] ghrelin, both in assay buffer.
  • assay buffer 50 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, EDTA-free protease inhibitor tablets—1 tablet/50 ml buffer, pH 7.4
  • 25 ⁇ g/ml hGHSR1a membrane 25 ⁇ g/ml hGHSR1a membrane
  • 50 ⁇ l of 100 ⁇ M [ 125 I] ghrelin both in
  • the mixture is incubated for 90 minutes at room temperature followed by transfer to a 0.3% PEI-treated, 96-well glass fiber filtration plate (Perkin Elmer, 6005174).
  • the mixture is suctioned dry with vacuum and immediately washed 3 times with 200 ⁇ l ice cold 50 mM Tris pH 7.5. Plates are allowed to dry overnight at room temperature and 30 ⁇ l Supermix scintillant (Perkin Elmer, 1200-439) is added to each well.
  • the amount of receptor-ligand complex is determined by liquid scintillation counting using a 1450 Microbeta Trilux (Wallac).
  • Radioligand binding filtration format assays for dog (NM — 001099945.1), monkey (XM — 001084886.1), mouse (NM — 177330), and rat (NM — 032075) GHSR1a (all expressed in unique HEK293 Tetracycline-Inducible cell lines) are performed in an identical manner as described for human GHSR1a except that the final amount of membrane to be used is as follows: 2 ⁇ g dog GHSR, 250 ng monkey GHSR, 200 ng mouse GHSR, or 125 ng rat GHSR.
  • a DELFIA GTP-binding assay (Perkin Elmer, AD0260 and AD0261) is performed.
  • the assay monitors the ligand-dependent exchange of GDP for GTP.
  • GPCR activation results in an increase in fluorescence as receptor-bound GDP is replaced by Europium-labeled GTP.
  • Antagonist binding prevents GDP-GTP exchange whereas binding of an inverse agonist pushes the receptor to the GDP bound (inactive) state, both resulting in decreased fluorescence.
  • Ghrelin functional assays are performed in a final volume of 39.5 ⁇ l containing 720 ng human GHSR1a (HEK293 Tetracycline-Inducible cell line expressing the human growth secretagogue receptor la, prepared as membranes), 9 nM GTP-Europium and varying concentrations of test compound or vehicle.
  • membranes are incubated in the presence of agonist ghrelin (Anaspec, 24158) at the EC 80 concentration, plus test compound or vehicle.
  • test compounds are prepared at room temperature in 384-well plates (Matrix, 4340).
  • the test compounds are first diluted in DMSO then added as 15 ⁇ l to 10 ⁇ l of basal buffer (50 mM HEPES pH 7.4, 3.7 mM MgCl 2 , 250 ⁇ M EGTA, 125 nM GDP) with and without 9 nM ghrelin peptide.
  • Samples are then transferred as 6 ⁇ l to 384-well filter plates (Pall, 5071) containing 30 ⁇ l of 24 ⁇ g/ml hGHSR1a membrane and 0.35 mg/ml saponin (Perkin Elmer, AD0261) in basal buffer.
  • the mixture is incubated 24 minutes at room temperature with gentle shaking, followed by the addition of 3.5 ⁇ l of 100 nM GTP-Europium in 50 mM HEPES, pH 7.4. Samples are shielded from light and incubated for 90 minutes further at room temperature with gentle shaking. The reactions are suctioned dry with vacuum, washed three times with 75 ⁇ l ice cold 1 ⁇ GTP Wash Solution (Perkin Elmer, AD0261), and immediately read on the Envision 2101 Multilabel Reader (Perkin Elmer) using excitation filter 320 nm and emission filter 615 nm.
  • Day 1 Human islet cells in an intravenous (iv) bag are obtained.
  • the islet cells are decanted by attaching a coupler to the iv bag and the liquid is decanted into 50 mL conical tubes.
  • the bag is rinsed with 20 mL of media and pooled.
  • the cells are spun 1 minute at 1000 revolutions per minute (rpm).
  • the cells are then incubated overnight at 37° C., 5% CO 2 (10 cm 2 suspension dishes, 10 mL media/plate).
  • Day 2 The islet cells are transferred to a 50 mL conical tube, Hank's Working Buffer without calcium is added and mixed, then the mixture is spun for 1 minute at 1000 rpm. The islets are then washed with Hank's Working Buffer without calcium, mixed and then spun at 1000 rpm for 1 minute. All but 15 mL of buffer is then removed by pipette. 30 ⁇ L of 500 mM EDTA [1 mM] is then added and then incubated 8 minutes at room temperature. To this is then added 75 ⁇ L of 0.25% Trypsin-EDTA and 15 ⁇ l of 2 mg/ml DNAse I [2 ⁇ g/ml]. The mixture is incubated for 10 minutes at 30° C.
  • the culture media is replaced with 100 ⁇ l of incubation buffer containing 3 mM glucose.
  • the plates are spun for 5 minutes at 1000 rpm to re-pellet the islets.
  • the plates are spun for 5 minutes at 1000 rpm to re-pellet the cells.
  • the plates are returned to a waterbath continuously gassed with 95% O 2 /5% CO 2 for 60 minutes. Transfered 40 ⁇ l to another plate and assay for insulin using an ELISA Human Insulin Assay (ALPCO Human Insulin ELISA; Cat. No. 80-INSHU-E10 available from ALPCO, Salem, N.H., USA).
  • ALPCO Human Insulin ELISA ELISA Human Insulin As
  • Pharmacological Data Table 1 The following pharmacological data provided in Pharmacological Data Table 1 was obtained for the compounds of the present invention.
  • the IC50 and Ki data was obtained from the Human Ghrelin SPA Binding Assay and is reported in nanomolar concentration of the test compound.
  • the column denoted “n” is the number of times the compound was assayed.
  • the functionality of the test compound, when indicated, was determined using the Human Ghrelin Functional Assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/049,225 2010-03-19 2011-03-16 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives Active 2032-01-05 US8609680B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/049,225 US8609680B2 (en) 2010-03-19 2011-03-16 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
US14/083,275 US20140080756A1 (en) 2010-03-19 2013-11-18 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31552210P 2010-03-19 2010-03-19
US201161444401P 2011-02-18 2011-02-18
US13/049,225 US8609680B2 (en) 2010-03-19 2011-03-16 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/083,275 Continuation US20140080756A1 (en) 2010-03-19 2013-11-18 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives

Publications (2)

Publication Number Publication Date
US20110230461A1 US20110230461A1 (en) 2011-09-22
US8609680B2 true US8609680B2 (en) 2013-12-17

Family

ID=44647714

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/049,225 Active 2032-01-05 US8609680B2 (en) 2010-03-19 2011-03-16 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
US14/083,275 Abandoned US20140080756A1 (en) 2010-03-19 2013-11-18 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/083,275 Abandoned US20140080756A1 (en) 2010-03-19 2013-11-18 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives

Country Status (26)

Country Link
US (2) US8609680B2 (da)
EP (1) EP2547679B1 (da)
JP (1) JP5496409B2 (da)
KR (1) KR101455917B1 (da)
CN (1) CN102939290B (da)
AR (1) AR080688A1 (da)
AU (1) AU2011228699B2 (da)
BR (1) BR112012023664B1 (da)
CA (1) CA2792234C (da)
CY (1) CY1118721T1 (da)
DK (1) DK2547679T3 (da)
ES (1) ES2557895T3 (da)
HK (1) HK1182094A1 (da)
HR (1) HRP20151232T1 (da)
HU (1) HUE025774T2 (da)
IL (1) IL221952A (da)
ME (1) ME02330B (da)
MX (1) MX2012010772A (da)
PL (1) PL2547679T3 (da)
PT (1) PT2547679E (da)
RS (1) RS54383B1 (da)
RU (1) RU2524341C2 (da)
SG (1) SG183812A1 (da)
SI (1) SI2547679T1 (da)
TW (1) TWI410423B (da)
WO (1) WO2011114271A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750745B2 (en) 2014-03-17 2017-09-05 Remynd Nv 2,7-diazaspiro[3.5]nonane compounds

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273263B2 (en) * 2012-06-04 2017-08-24 Pfizer Inc. Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
PL2861566T3 (pl) * 2012-06-13 2017-06-30 F.Hoffmann-La Roche Ag Nowy diazaspirocykloalkan i azaspirocykloalkan
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
MX2016005186A (es) 2013-11-26 2016-07-08 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX2020004504A (es) 2015-09-04 2021-11-10 Hoffmann La Roche Derivados de fenoximetilo.
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
CN115124538A (zh) 2015-09-24 2022-09-30 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180096406A (ko) 2017-02-21 2018-08-29 엘지전자 주식회사 냉장고
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
KR102647257B1 (ko) * 2017-07-28 2024-03-13 케모센트릭스, 인크. 면역조절제 화합물
CN108588215A (zh) * 2018-05-03 2018-09-28 成都中创清科医学检验所有限公司 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法
CN109970631A (zh) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 一种5-碘-2-吡啶乙酸的合成方法
CN110256349B (zh) * 2019-04-23 2020-09-08 苏州大学 多取代吡唑及其制备方法
CN110172062B (zh) * 2019-06-21 2022-01-07 南京药石科技股份有限公司 一种单氟代螺环化合物的合成方法及其中间体
CN115461334B (zh) 2020-11-27 2024-06-21 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
KR20220001745U (ko) 2021-01-06 2022-07-13 성보라 자동차시트 후면 보호용 보조커버

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2005040167A1 (en) 2003-10-23 2005-05-06 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
WO2007007069A1 (en) 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
WO2008033456A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
US20090169567A1 (en) 2005-11-18 2009-07-02 Ono Pharmaceutical Co., Ltd., Basic group-containing compound and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303376A3 (en) 2001-02-28 2007-08-28 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
SI1753748T1 (sl) 2004-05-12 2009-12-31 Pfizer Prod Inc Derivati prolina in njihova uporaba kot inhibitorji dipeptidil-peptidaze IV
WO2005116034A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
US20090270435A1 (en) 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2727914A1 (en) * 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
CA2733795C (en) 2008-08-28 2013-12-31 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
CN102388038B (zh) 2009-03-11 2014-04-23 辉瑞大药厂 用作葡糖激酶活化剂的苯并呋喃基衍生物
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
WO2010141817A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
MA33334B1 (fr) 2009-06-05 2012-06-01 Pfizer Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2005040167A1 (en) 2003-10-23 2005-05-06 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
WO2007007069A1 (en) 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
US20090169567A1 (en) 2005-11-18 2009-07-02 Ono Pharmaceutical Co., Ltd., Basic group-containing compound and use thereof
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
WO2008033456A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism

Non-Patent Citations (75)

* Cited by examiner, † Cited by third party
Title
Ando et al., Am. J. Clin. Nutr., 86, pp. 25-32, 2007.
Andralojc et al., Diabetologia, 52, pp. 486-493, 2009.
Ariyasu et al., J. Clin. Endocrinol. Metab., 86, pp. 4753-4758, 2001.
Arosia et al., J. Clin. Endocrinol. Metab, 88, pp. 701-704, 2003.
Asakawa et al., Gut, 52, pp. 947-952, 2003.
Barazzoni et al., J. Clin. Endocrinol. & Met., 92, pp. 3935-3940, 2007.
Broglio et al., J. Clin. Endocrinol. Metab., 86, pp. 5083-5086, 2001.
Broglio et al., J. Clin. Endocrinol. Metab., 87, pp. 3783-3790, 2002.
Broglio et al., J. Clin. Endocrinol. Metab., 88, pp. 1537-1542, 2003a.
Broglio et al., J. Clin. Endocrinol. Metab., 89, pp. 3062-3065, 2004.
Broglio et al., J. Endocrinol. Invest., 26, pp. 192-196, 2003b.
Carpino et al., Expert Opinion on Therapeutic Patents, 12(11), p. 1599-1618, 2002.
Carpino et al., Expert Opinion on Therapeutic Patents, 18(11), p. 1253-1263, 2008.
Chen et al., Pharm. Rev., 61, pp. 430-481, 2009.
Chung et al., Hum. Hered., 67, pp. 193-205, 2009.
Colombo et al., Pancreas, 27, pp. 161-166, 2003.
Cummings et al., Diabetes, 50, pp. 1714-1719, 2001.
Cummings et al., N. Engl. J. Med., 346, pp. 1623-1630, 2002.
Damjanovic et al., J. Clin. Endocrinol. Metab., 91, pp. 2574-2581, 2006.
Date et al., Diabetes, 51, pp. 124-129, 2002.
Date et al., Endocrinology, 141, pp. 4255-4261, 2000.
Dezaki et al., Diabetes, 53, pp. 3142-3151, 2004.
Dezaki et al., Diabetes, 55, pp. 3486-3493, 2006.
Dezaki et al., Diabetes, 56, pp. 2319-2327, 2007.
Dezaki et al., Pharmacology & Therapeutics, 118, pp. 239-249, 2008.
Dornonville de la Cour et al., Reg. Pept., 99, pp. 141-150, 2001.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. and p. 10. *
Druce et al., Int. J. Obes., 29, pp. 1130-1136, 2005.
Egido et al., Eur. J. Endocrinol, 146, pp. 241-244, 2002.
Esler et al., Endocrinology, 148, pp. 5175-5185, 2007.
Gauna et al., J. Clin. Endocrinol. Metab., 89, pp. 5035-5042, 2004.
Gnanapavan et al., J. Clin. Endocrinol. Metab., 87, pp. 2988-2991, 2002.
Gualillo et al., Endocrinology, 142, pp. 788-794, 2001.
Hattori et al., J. Clin. Endocrinol. Metab., 86, pp. 4284-4291, 2001.
Hosoda et al., Biochem. Biophys. Res. Commun., 279, pp. 909-913, 2000.
Huda et al., Int. J. Obesity, 33, pp. 317-325, 2009.
Klipelainen et al., Metabolism, 57, pp. 428-436, 2008.
Kojima et al., Nature, 402, pp. 656-660, 1999.
Korbonits et al., J. Clin. Endocrinol. Metab., 87, pp. 4004-4008, 2002.
Li et al., Chin. Med. J., 121, pp. 1666-1669, 2008.
Longo et al., Reg. Peptides, 150, pp. 55-61, 2008.
Lu et al., Neuroscience Lett., 321, pp. 157-160, 2002.
Lucidi et al., Nutr. Metab. Cardiovasc. Dis., 15, pp. 410-417, 2005.
lwakura et al., Am. J. Physiol. Endocrinol. Metab., 297, pp. 802-811, 2009.
Mager et al., Diabet. Med., 23(6), pp. 685-689, 2006.
Mondal et al., Regul. Pept., 126, pp. 55-59, 2005.
Mori et al., FEBS let., 486, pp. 213-216, 2000.
Muccioli et al., Eur. J. Pharmacol, 440, pp. 235-254, 2002.
Nakazato et al., Nature, 409, pp. 194-198, 2001.
Poykko et al., Diabetologia, 46, pp. 455-458, 2003.
Reimer et al., Endocrinology, 144, pp. 916-921, 2003.
Rindi et al., Histochem. Cell Biol., 117, pp. 511-519, 2002.
Robitaille et al., Obesity, 15, pp. 2336-2347, 2007.
Rodriquez et al., Int. J. Obes., 33, pp. 541-552, 2009.
Roth et al., Obes. Surg., 19, pp. 29-35, 2008.
Sakata et al., Peptides, 23, pp. 531-536, 2002.
Shuto et al., J. Clin. Invest., 109, pp. 1429-1436, 2002.
Sun et al., Cell Metab., 3, pp. 379-386, 2006.
Suvi Simila, et al., ACS National Meeting Poster Abstract, Washington DC, Aug. 2009.
Tanaka et al., Biochim. Biophys. Acta., 1522, pp. 62-65, 2001.
Tang et al., Clin. Chim. Acta., 387, pp. 42-47, 2008.
Tena-Sempere et al., Endocrinology, 143, pp. 717-725, 2002.
Tong et al. ADA Conference, "Ghrelin Suppresses Glucose-Stimulated Insulin Secretion in Healthy Humans", 2009.
Ukkola et al., Obes. Res., 10, pp. 782-791, 2002.
Vestergaard et al., Am. J. Physiol. Endocrinol. Metab., 292, pp. E1829-E1836, 2007.
Vestergaard et al., Diabetes, 57, pp. 3205-3210, 2008b.
Vestergaard et al., J. Clin. Endocinol. Metabol., 93, pp. 438-444, 2008a.
Volante et al., J. Clin. Endocrinol. Metab., 87, pp. 1300-1308, 2002a.
Volante et al., J. Histochem. Cytochem., 50, pp. 1013-1021, 2002b.
Wierup et al., Cell Tissue Res., 319, pp. 423-428, 2005.
Wierup et al., J. Hostochem. Cytochem., 52, pp. 301-310, 2004.
Wierup et al., Regul. Pept., 107, pp. 63-69, 2002.
Wortley et al., J. Clin. Invest., 115, pp. 3573-3578, 2005.
Wren et al., J. Clin. Endocrinol. Metab., 86, pp. 5992-5995, 2001.
Zigman et al., J. Clin. Invest., 115, pp. 3564-3572, 2005.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750745B2 (en) 2014-03-17 2017-09-05 Remynd Nv 2,7-diazaspiro[3.5]nonane compounds

Also Published As

Publication number Publication date
KR20130001276A (ko) 2013-01-03
MX2012010772A (es) 2012-11-06
CN102939290A (zh) 2013-02-20
RS54383B1 (en) 2016-04-28
HRP20151232T1 (hr) 2015-12-18
AU2011228699A1 (en) 2012-09-20
EP2547679B1 (en) 2015-11-04
PT2547679E (pt) 2016-01-27
IL221952A (en) 2016-02-29
TW201144312A (en) 2011-12-16
US20140080756A1 (en) 2014-03-20
US20110230461A1 (en) 2011-09-22
KR101455917B1 (ko) 2014-11-03
CA2792234A1 (en) 2011-09-22
HUE025774T2 (en) 2016-05-30
ES2557895T3 (es) 2016-01-29
CN102939290B (zh) 2015-09-16
CA2792234C (en) 2014-05-27
WO2011114271A8 (en) 2012-11-08
CY1118721T1 (el) 2017-07-12
HK1182094A1 (zh) 2013-11-22
TWI410423B (zh) 2013-10-01
AU2011228699B2 (en) 2016-05-19
PL2547679T3 (pl) 2016-02-29
BR112012023664A2 (pt) 2016-08-16
ME02330B (me) 2016-06-20
DK2547679T3 (da) 2016-01-11
SG183812A1 (en) 2012-10-30
JP2013522354A (ja) 2013-06-13
JP5496409B2 (ja) 2014-05-21
WO2011114271A1 (en) 2011-09-22
AR080688A1 (es) 2012-05-02
RU2012137489A (ru) 2014-04-27
BR112012023664B1 (pt) 2020-01-28
SI2547679T1 (sl) 2015-12-31
EP2547679A1 (en) 2013-01-23
RU2524341C2 (ru) 2014-07-27

Similar Documents

Publication Publication Date Title
US8609680B2 (en) 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
US9181252B2 (en) N1/N2-lactam acetyl-CoA carboxylase inhibitors
US8507681B2 (en) N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8802688B2 (en) Substituted acetyl-coa carboxylase inhibitors
US20120052130A1 (en) Gpr 119 modulators
JP2015515472A (ja) ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
US20100285145A1 (en) Gpr 119 modulators
US20230052017A1 (en) New compounds for treatment of diseases related to DUX4 expression
OA16631A (en) Pyrazolospiroketone derivatives for use as ACETYL-COA Carboxylase inhibitors

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BHATTACHARYA, SAMIT K.;CAMERON, KIMBERLY O.;MCCLURE, KIM F.;AND OTHERS;SIGNING DATES FROM 20100319 TO 20100406;REEL/FRAME:035103/0170

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BHATTACHARYA, SAMIT K.;CAMERON, KIMBERLY O.;FERNANDO, DILINIE P.;AND OTHERS;REEL/FRAME:035155/0362

Effective date: 20110224

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNORS' NAMES AND EXECUTION DATES PREVIOUSLY RECORDED AT REEL: 035155 FRAME: 0362. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:BHATTACHARYA, SAMIT K.;CAMERON, KIMBERLY O.;FERNANDO, DILINIE P.;AND OTHERS;REEL/FRAME:035205/0555

Effective date: 20110224

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNEE ADDRESS CORRECTION;ASSIGNOR:PFIZER INC.;REEL/FRAME:063119/0087

Effective date: 20230307